(Q40575606)

21 September 2017

title

Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma (English)

1 reference

21 September 2017

1

Alexander Marmé

0 references

Gerhard Moldenhauer

5

object named as

Gerhard Moldenhauer

1 reference

21 September 2017

Alexander Marmé

1

1 reference

21 September 2017

Gudrun Strauss

2

1 reference

21 September 2017

Gunther Bastert

3

1 reference

21 September 2017

Eva-Maria Grischke

4

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

International Journal of Cancer

21 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

21 September 2017

volume

101

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

183-189

1 reference

21 September 2017

cites work

Cancer statistics, 2000.

1 reference

Ovarian cancer chemotherapy

21 January 2018

1 reference

Bispecific antibodies in cancer therapy

21 January 2018

1 reference

Of mice and men: hybridoma and recombinant antibodies

21 January 2018

1 reference

Immunotherapeutic perspective for bispecific antibodies

21 January 2018

1 reference

The biology of the 17-1A antigen (Ep-CAM)

21 January 2018

1 reference

Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker

21 January 2018

1 reference

Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

21 January 2018

1 reference

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

21 January 2018

1 reference

Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes

21 January 2018

1 reference

Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets.

21 January 2018

1 reference

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

21 January 2018

1 reference

Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo

21 January 2018

1 reference

Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis.

21 January 2018

1 reference

Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1.

21 January 2018

1 reference

Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.10562

1 reference

21 September 2017

1 reference